Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD5 | P21918 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26010448 | 0.82 | KMT2A (0.36) | CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL19617362 | 0.80 | KMT2A (0.34) | CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL28503146 | 0.78 | KMT2A (0.31) | CYP1A2CYP2C19DRD2DRD3KMT2A | |
| SCHEMBL21777116 | 0.78 | KMT2A (0.38) | CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL19617493 | 0.76 | PARP1 (0.40) | KMT2A | |
| SCHEMBL24780348 | 0.75 | CYP1A2 (0.37) | CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL29903126 | 0.75 | CYP1A2 (0.37) | CYP1A2CYP2C19KMT2AGAA | |
| SCHEMBL21777078 | 0.74 | CCNA2 (0.37) | KMT2AGAA | |
| SCHEMBL26010297 | 0.74 | KDM4E (0.34) | CYP1A2CYP2C19GAA | |
| SCHEMBL28535555 | 0.73 | C5AR1 (0.41) | CYP1A2DRD2DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739102-B2 | Fused pyrimidine compounds as KRAS inhibitors | INCYTE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739102-B2 | Fused pyrimidine compounds as KRAS inhibitors | KRAS, NRAS, HRAS | CYP1A2 4171/4885CYP2C19 3567/4885DRD2 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.